CASI News and Press, CASI Pharmaceuticals Inc. From 09/23/22

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET PR Newswire ROCKVILLE, Md. and BEIJING , Sept. 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on devel...

Summary Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Nanjing Frontier Biotechnologies completed a $29 million private placemen...

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA PR Newswire ROCKVILLE, Md. and LUND, Sweden , Sept. 7, 2022 /PRNewswire/ -- ...

Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...

CASI Pharmaceuticals, Inc. (CASI) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief Executive Officer Alex Zukiwski – Executive Vice President and Chief ...

CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q2 GAAP EPS of -$0.56. Revenue of $8.57M (+19.7% Y/Y) beats by $0.7M . As of June 30, 2022, CASI had cash and cash equivalents of $18.9 million. Shares -6.41% PM. For further details see: CASI P...

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire ROCKVILLE, Md. and BEIJING , Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercia...

CASI Pharmaceuticals ( NASDAQ: CASI ) is scheduled to announce Q2 earnings results on Friday, August 12th, before market open. The consensus EPS Estimate is -$0.61 (-1120.0% Y/Y) and the consensus Revenue Estimate is $7.87M (+9.9% Y/Y). Over the last 3 months, EPS esti...

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 PR Newswire ROCKVILLE, Md. and BEIJING , Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical com...

InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...